GEN Exclusives

More »

GEN News Highlights

More »
Nov 12, 2009

Altair Raises $17M to Progress Phase II Trials with Antisense Asthma Treatment

  • Altair Therapeutics obtained $17 million in a financing round to complete mid-stage trials with lead asthma product, inhaled AIR645, and progress new target programs. AIR645 is a second-generation, modified antisense drug targeting the alpha subunit of the human IL-4 receptor, which is also required for IL-13 activity.

    During September Altair reported positive results from a Phase I multiple dose-safety and pharmacokinetic study of once-weekly inhaled AIR645 in healthy adults and mild asthmatics. “AIR645 is based upon a proprietary antisense molecular design termed MOE gapmer that greatly improves potency, stability, safety, and tolerability in vivo,” points out Joel F. Martin Ph.D., Altair president and CEO.

    “AIR645 is the first such MOE gapmer oligonucleotide to be administered by inhalation in man and has now demonstrated favorable safety and pharmacokinetic profiles. The results are particularly remarkable because AIR645, a low cost-of-goods drug, inhibits a target that, to date, has been approachable only by expensive biologics.”

    Altair licensed a technology for the chemical modification of antisense oligonucleotides from Isis Pharmaceuticals. The firms are also collaborating to discover inhaled 2´-MOE gapmers for other promising targets, which have not yet been disclosed, for the treatment of respiratory conditions.


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »